Biocryst Pharmaceuticals reported $604.46M in Loan Capital for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
DBV Technologies DBVT:US 0 0
Alnylam Pharmaceuticals ALNY:US $ 677.72M 1.01M
Chemocentryx CCXI:US $ 4M 0.55M
Chugai Pharma 4519:JP Y 0M 0M
Daiichi Sankyo 4568:JP Y 142973M 94M
Enanta Pharmaceuticals ENTA:US $ 1.51M 0M
Glaxosmithkline GSK:US $ 18784M 10442M
GlaxoSmithKline GSK:LN 18784M 10442M
Intra Cellular Therapies ITCI:US $ 0M 0M
IONIS PHARMACEUT IONS:US $ 1248.4M 0.47M
Karyopharm Therapeutics KPTI:US $ 302.69M 202K
Mirati Therapeutics MRTX:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 169M 208.7M
Ptc Therapeutics PTCT:US $ 981.44M 5.79M
Regeneron Pharmaceuticals REGN:US $ 2700.7M 0.3M
Sarepta Therapeutics SRPT:US $ 1100.87M 2.03M
Ultragenyx Pharmaceutical RARE:US $ 0M 0M
Vertex Pharmaceuticals VRTX:US $ 482.3M 13.2M
YTE INCY:US $ 31.16M 0.23M